Nash, P., Coates, L. C., Fleishaker, D., Kivitz, A. J., Mease, P. J., Gladman, D. D., FitzGerald, O., Wang, C., Wu, J., Hsu, M.-A., Menon, S., Fallon, L., & Kanik, K. S. (2021). Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. Lancet.

Nash, P., et al. “Safety and Efficacy of Tofacitinib up to 48 Months in Patients with Active Psoriatic Arthritis: Final Analysis of the OPAL Balance Long-Term Extension Study.” Lancet, Lancet, 2021.

Nash, P, LC Coates, D Fleishaker, AJ Kivitz, PJ Mease, DD Gladman, O FitzGerald, et al. 2021. “Safety and Efficacy of Tofacitinib up to 48 Months in Patients with Active Psoriatic Arthritis: Final Analysis of the OPAL Balance Long-Term Extension Study.” Lancet.